UroGen Pharma Revenue vs. Return On Asset
| URGN Stock | USD 11.91 0.36 3.12% |
Total Revenue | First Reported 2015-12-31 | Previous Quarter 21.8 M | Current Value 25.2 M | Quarterly Volatility 8.9 M |
For UroGen Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of UroGen Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well UroGen Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between UroGen Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of UroGen Pharma over time as well as its relative position and ranking within its peers.
UroGen |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
UroGen Pharma Return On Asset vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining UroGen Pharma's current stock value. Our valuation model uses many indicators to compare UroGen Pharma value to that of its competitors to determine the firm's financial worth. UroGen Pharma is rated first in revenue category among its peers. It is rated below average in return on asset category among its peers . At this time, UroGen Pharma's Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the UroGen Pharma's earnings, one of the primary drivers of an investment's value.UroGen Revenue vs. Competition
UroGen Pharma is rated first in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 175.05 Million. UroGen Pharma totals roughly 82.71 Million in revenue claiming about 47% of equities under Health Care industry.
UroGen Return On Asset vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
UroGen Pharma |
| = | 82.71 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
UroGen Pharma |
| = | -0.21 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
UroGen Return On Asset Comparison
UroGen Pharma is currently under evaluation in return on asset category among its peers.
UroGen Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in UroGen Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, UroGen Pharma will eventually generate negative long term returns. The profitability progress is the general direction of UroGen Pharma's change in net profit over the period of time. It can combine multiple indicators of UroGen Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 12 K | 12.6 K | |
| Operating Income | -65.5 M | -68.8 M | |
| Net Loss | -105.1 M | -99.8 M | |
| Income Before Tax | -98.3 M | -93.4 M | |
| Total Other Income Expense Net | -32.8 M | -31.1 M | |
| Net Loss | -98.8 M | -93.9 M | |
| Net Loss | -102.2 M | -97.1 M | |
| Income Tax Expense | 3.9 M | 4.1 M | |
| Interest Income | 2.4 M | 1.9 M | |
| Net Interest Income | -11.9 M | -11.3 M | |
| Non Operating Income Net Other | 1.2 M | 672.1 K | |
| Change To Netincome | 13.2 M | 15.3 M | |
| Net Loss | (3.55) | (3.72) | |
| Income Quality | 0.75 | 0.78 | |
| Net Income Per E B T | 1.04 | 0.81 |
UroGen Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on UroGen Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of UroGen Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the UroGen Pharma's important profitability drivers and their relationship over time.
Use UroGen Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.UroGen Pharma Pair Trading
UroGen Pharma Pair Trading Analysis
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your UroGen Pharma position
In addition to having UroGen Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alcohol Thematic Idea Now
Alcohol
Companies involved in production and distribution of wines and alcoholic beverages. The Alcohol theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alcohol Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
To fully project UroGen Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of UroGen Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include UroGen Pharma's income statement, its balance sheet, and the statement of cash flows.